Polycystic ovarian syndrome (PCOS) is the accumulation of underdeveloped follicles in the ovaries due to anovulation. It is is characterized by menstrual abnormalities and clinical or biochemical features of hyperandrogenism.
It results mainly from abnormal steroidogenesis that may be caused by insulin resistance leading to hyperinsulinemia.
There is increased sensitivity to androgens and the majority of women have elevated androgen levels.
Sedentary behaviour remains extremely prevalent among overweight or obese women with polycystic ovary syndrome (PCOS), with a recent study reporting that only one in two women meets physical activity (PA) levels recommended for weight loss.
Middle-aged women with polycystic ovary syndrome (PCOS) exhibit only a moderately unfavourable cardiometabolic profile despite having an increased body mass index (BMI) and waist circumference, as reported in a study.
In the management of women with polycystic ovary syndrome (PCOS) and obesity, rosiglitazone monotherapy or in combination with low-dose metformin plus lifestyle modification should be recommended to those with abnormal lipid profiles, according to the results of a trial.
Hyperinsulinaemia and insulin resistance appear to exacerbate phenotypic characteristics, reproductive endocrine disorders, and glucose and lipid metabolic dysfunction in polycystic ovary syndrome (PCOS) patients and therefore lead to reduced fertility in these women, a study has found.
Use of oral contraceptive agents in combination with metformin or lifestyle changes appears to effectively reduce the adverse impact of polycystic ovary syndrome (PCOS) on glucose and lipid metabolism in overweight women, according to the results of a network meta-analysis.
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
Infants born to mothers with polycystic ovary syndrome (PCOS) are less likely to be large for gestational age, according to data from the SCOPE* cohort study. Moreover, PCOS does not carry an increased risk of pregnancy complications in women following a healthy lifestyle.
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.